In 2013, the main causes of death in France was cancer. That year 163,602 French individuals died of cancer, regardless of gender. Diseases appear to be the leading causes of death in Europe and Western countries. Ischaemic heart diseases, as well as other circulatory system diseases kill millions of Europeans every year.

Diseases are the leading causes of death in France and worldwide

In 2018, there were more than 601,000 deaths in France. Most of them were caused by cancer and other diseases. Tumor is the leading cause of death among French men, while women seem more affected by heart diseases. In Europe in 2016, the cause of death with the greatest likelihood of death was cancer, which occurred in 265 people out of every 100,000 Europeans. Despite the development of medicine and technological progress, health issues like cancers keep being the main causes of death among the human population.

The increase of life expectancy

Even though tumors and other heart diseases are responsible for the majority of deaths in the world, it appears that medical advances in the last years and decades have a real impact on mortality rate worldwide. Between 2007 and 2017 alone, the global death rate went from 8.08 deaths per 1,000 inhabitants to 7.62. Similarly, the global child mortality rate has fallen steadily across the world since the sixties. These different factors had led to an increase of life expectancy. In 2016, the average life expectancy at birth worldwide reached 72 years, compared to 64 years in 1990.

The mortality rate has been stable in France since the middle of 1980s. The mortality rate varies between ten and eight deaths per 1,000 inhabitants. Life expectancy of women in France amounted to more than 85 years in 2024, making the country one of the areas in Europe where women live the longest. A slowly increasing death rate From 2014 to 2020, the death rate in France generally remained stable, oscillating mostly between 8.4 and 9.9 deaths per 1,000 population. Death rate, also known as mortality rate, is the ratio between the annual number of deaths and the average total population over a given period and in a specific territory. In 2024, the population in France reached 68.44 million people, while in 2023, the total number of deaths in France was 639,269. The mortality rate in France increased slowly in recent years. In 2007, the death rate amounted to 8.3 per thousand population, compared to 9.1 deaths ten years later. Causes of death In 2013, the leading cause of death among French citizens was cancer. That year, 163,602 people died of tumors, while diseases of the circulatory system were the second most common cause of death in the country. Mortality rate because of cancer was particularly high among French males, whereas females appear to be more affected by cardiovascular disease. Studies have shown that cancer was not only the leading cause of death in France, but also in Europe. More broadly, health and diseases were among the major causes of death in European countries, even if traffic accidents killed more than 3,167 individuals in France in 2023.

This graph presents the distribution of the leading causes of death among women in France in 2017. The statistic reveals that 75.8 thousand French women died from circulatory system diseases that year.

This graph illustrates the distribution of young people and children who died in France in 2014, by age and cause of death. That year, about 60 percent of people being between 15 and 14 years old died from external causes such as accidents or suicide.

In 2032, there were 639,269 deaths in France. Of course, this figure must be related to the total population. In 2024, the death rate in France was 9.4 per 1,000 inhabitants. Deaths in France Despite being the second most populous country in Europe, France was ranked fourth in terms of the number of deaths in Europe in 2017. As in other Western countries, the leading causes of death among the French population appear to be diseases and cancer. In 2017, more than 73 thousand French women died of cancer. Circulatory system diseases were also one of the most frequent causes of death. Regarding external causes of death, France has been fighting for years against road deaths. Prevention campaigns, as well as new traffic regulations, have led to a decrease in road deaths in France since 2006. Aging in France France has one of the highest life expectancies in Europe. The French appear to be concerned about health issues, now that the population of the country is getting older. However, since the mid-2000s, the number of healthy life years of French male citizens at birth has over 63 years, whereas it reaches 58 years in Germany.

The National Health Data System (SNDS) will make it possible to link:

• health insurance data (SNIIRAM database);
• hospital data (PMSI database);
• the medical causes of death (base of the CépiDC of Inserm);
• disability-related data (from MDPH - CNSA data);
• a sample of data from complementary health insurance organisations.

The first two categories of data are already available and constitute the first version of the SNDS. The medical causes of death should feed the SNDS from the second half of 2017. The first data from the CNSA will arrive from 2018 and the sample of complementary organizations in 2019.

The purpose of the SNDS is to make these data available in order to promote studies, research or evaluations of a nature in the public interest and contributing to one of the following purposes:

• health information;
• the implementation of health policies;
• knowledge of health expenditure;
• informing professionals and establishments about their activities;
• innovation in the fields of health and medico-social care;
• monitoring, surveillance and health security.

BackgroundIn the beginning of the 1970s, Sweden was the country where both women and men enjoyed the world's longest life expectancy. While life expectancy continues to be high and increasing, Sweden has been losing ground in relation to other leading countries.MethodsWe look at life expectancy over the years 1970–2008 for men and women. To assess the relative contributions of age, causes of death, and smoking we decompose differences in life expectancy between Sweden and two leading countries, Japan and France. This study is the first to use this decomposition method to observe how smoking related deaths contribute to life expectancy differences between countries.ResultsSweden has maintained very low mortality at young and working ages for both men and women compared to France and Japan. However, mortality at ages above 65 has become considerably higher in Sweden than in the other leading countries because the decrease has been faster in those countries. Different trends for circulatory diseases were the largest contributor to this development in both sexes but for women also cancer played a role. Mortality from neoplasms has been considerably low for Swedish men. Smoking attributable mortality plays a modest role for women, whereas it is substantially lower in Swedish men than in French and Japanese men.ConclusionsSweden is losing ground in relation to other leading countries with respect to life expectancy because mortality at high ages improves more slowly than in the leading countries, especially due to trends in cardiovascular disease mortality. Trends in smoking rates may provide a partial explanation for the trends in women; however, it is not possible to isolate one single explanatory factor for why Sweden is losing ground.

Context

The Marseille IHU Méditerranée Infection :

The Mediterranean Infection Foundation aims to condense the means of fighting infectious diseases, the leading cause of death in the world (17 million deaths per year) and in particular the three world killers (HIV, tuberculosis and malaria), into a major and strategic pole with local, national and international influence.

The IHU of Marseille is the first French try of fighting the Covid19 with the help of the Chloroquine. More tests are currently made and this data will be updated when new information is released.

Content

For more information and see the original studies and result follow this link : https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf

Inspiration

The trial is containing for now a really small amount of subjects. More will come in update to the next few weeks. This experiment preceded the Discovery trial by the EU. The Data should be used to determine if yes or not the Chloroquine as an effect on the Covid19.

This statistic presents the results of a survey on the perception of the French of the main causes of road mortality in 2017, by region. In Brittany and Normandy, ** percent of respondents considered driving under the influence of alcohol or narcotics to be the main cause of fatal accidents on roads in general.

Immuno Oncology Diagnosis Market Outlook

The global immuno oncology diagnosis market size was valued at $2.5 billion in 2023 and is projected to reach $7.9 billion by 2032, growing at a compound annual growth rate (CAGR) of 13.7% during the forecast period. This marketÂ’s growth is driven primarily by the rising incidence of cancer and advancements in diagnostic technologies that enable early and precise detection of oncological conditions.

One of the primary growth factors for the immuno oncology diagnosis market is the increasing prevalence of cancer globally. According to the World Health Organization (WHO), cancer is one of the leading causes of death worldwide, with approximately 19.3 million new cases and 10 million cancer-related deaths in 2020. The rising cancer incidence necessitates advanced diagnostic solutions to ensure early detection and effective treatment, thereby driving the demand for immuno oncology diagnostics. Additionally, the growing awareness about the importance of early cancer diagnosis among the general population and healthcare providers further fuels market growth.

Another significant growth factor is the advancements in diagnostic technologies. Innovations such as next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), and flow cytometry have revolutionized the field of oncology diagnostics. These technologies offer enhanced accuracy, specificity, and sensitivity in detecting cancer biomarkers, thereby improving diagnostic outcomes. The integration of artificial intelligence (AI) and machine learning in diagnostic tools also holds immense potential for improving diagnostic efficiency and accuracy, further propelling market growth.

The increasing investment in cancer research and development by governments, healthcare organizations, and pharmaceutical companies is also a key driver for the market. Significant funding and grants are being allocated to cancer research initiatives to develop innovative diagnostic and treatment solutions. The collaboration between academic and research institutes, diagnostic laboratories, and biotechnology companies is fostering the development of advanced diagnostic assays, kits, and instruments, thereby contributing to market growth.

Immuno-Oncology is a rapidly evolving field that plays a crucial role in the development of innovative diagnostic and therapeutic solutions for cancer. This area focuses on harnessing the body's immune system to identify and combat cancer cells, offering a promising approach to cancer treatment. The integration of immuno-oncology in diagnostics has led to the development of advanced assays and biomarkers that enhance the precision of cancer detection and monitoring. By understanding the interactions between the immune system and cancer cells, researchers can develop targeted therapies that improve patient outcomes. The continuous advancements in immuno-oncology are expected to drive significant growth in the diagnostic market, providing new opportunities for early detection and personalized treatment strategies.

Regionally, North America holds the largest share of the immuno oncology diagnosis market, attributed to the presence of a well-established healthcare infrastructure, high adoption of advanced diagnostic technologies, and significant investment in cancer research. The Asia Pacific region is expected to witness the highest growth rate during the forecast period, driven by the increasing prevalence of cancer, improving healthcare infrastructure, and rising awareness about early cancer diagnosis. Europe also holds a significant market share, with countries like Germany, France, and the UK leading in cancer research and diagnostics.

Product Type Analysis

The product type segment of the immuno oncology diagnosis market includes assays, kits, reagents, instruments, and software. Assays are a crucial component in the diagnosis and monitoring of cancer as they provide detailed information about the presence and progression of the disease. These assays are designed to detect specific cancer biomarkers, thus aiding in accurate diagnosis and personalized treatment planning. The increasing demand for early and precise cancer diagnosis is driving the growth of the assays segment. Furthermore, the development of advanced assays with higher sensitivity and specificity is anticipated to boost the market growth.

Kits are another essential product type in the immuno oncology diagnosis

BackgroundCurrently, cardiovascular disease (CVD) is widely acknowledged to be the first leading cause of fatality in the world with 31% of all deaths worldwide and is predicted to remain as such in 2030. Furthermore, CVD is also a major cause of morbidity in adults worldwide. Among these diseases, the coronary artery disease (CAD) is the most common cause, accounting for over 40% of CVD deaths. Despite a decline in mortality rates, the consequences of more effective preventive and management programs, the burden of CAD remains significant. Indeed, the rise in the prevalence of modifiable risk factors due to changes in lifestyle and health behaviors has further increased the burden of this epidemic. Our objective was to evaluate the hospital burden of CAD via MI trends and Percutaneous Coronary Intervention (PCI) in the French Prospective Payment System (PPS).MethodsMI/PCI were identified in the national PPS database from 2009 to 2014 for patients aged 20 to 99, living in metropolitan France. We examined hospitalisation, readmission and mortality trends using standardised rates.ResultsOver the six-year period, we identified 678,021 patients, representing 900,121 stays of which, 215,224 had a MI and a PCI. Admission trends increased by nearly 25%. Acute MI cases increased every year, with an alarming increase in women, and more specifically in young women. Men were 3 times more hospitalised than women, who were older. A North-South divide was noted. Twenty seven percent of patients experienced readmission within 1 month. Trajectories of care were significantly different by sex and age. Overall in-hospital death was 3.3%, decreasing by 15% during the period. The highest adjusted mortality rates were observed for inpatients aged 80.ConclusionWe outlined the public health burden of this condition and the importance of improving the trajectories of care as an aid for better care.

This dataset contains data from WHO's data portal covering the following categories:

Adolescent, Ageing, Air pollution, Assistive technology, Child, Child mortality, Cross-cutting, Dementia diagnosis, treatment and care, Environment and health, Foodborne Diseases Estimates, Global Dementia Observatory (GDO), Global Health Estimates: Life expectancy and leading causes of death and disability, Global Information System on Alcohol and Health, Global Patient Safety Observatory, Global strategy, HIV, Health financing, Health systems, Health taxes, Health workforce, Hepatitis, Immunization coverage and vaccine-preventable diseases, Malaria, Maternal and newborn, Maternal and reproductive health, Mental health, Neglected tropical diseases, Noncommunicable diseases, Nutrition, Oral Health, Priority health technologies, Resources for Substance Use Disorders, Road Safety, SDG Target 3.8 | Achieve universal health coverage (UHC), Sexually Transmitted Infections, Tobacco control, Tuberculosis, Vaccine-preventable communicable diseases, Violence prevention, Water, sanitation and hygiene (WASH), World Health Statistics.

For links to individual indicator metadata, see resource descriptions.

This dataset contains data from WHO's data portal covering the following categories:

Adolescent, Ageing, Air pollution, Assistive technology, Child, Child mortality, Cross-cutting, Dementia diagnosis, treatment and care, Environment and health, Foodborne Diseases Estimates, Global Dementia Observatory (GDO), Global Health Estimates: Life expectancy and leading causes of death and disability, Global Information System on Alcohol and Health, Global Patient Safety Observatory, Global strategy, HIV, Health financing, Health systems, Health taxes, Health workforce, Hepatitis, Immunization coverage and vaccine-preventable diseases, Malaria, Maternal and newborn, Maternal and reproductive health, Mental health, Neglected tropical diseases, Noncommunicable diseases, Nutrition, Oral Health, Priority health technologies, Resources for Substance Use Disorders, Road Safety, SDG Target 3.8 | Achieve universal health coverage (UHC), Sexually Transmitted Infections, Tobacco control, Tuberculosis, Vaccine-preventable communicable diseases, Violence prevention, Water, sanitation and hygiene (WASH), World Health Statistics.

For links to individual indicator metadata, see resource descriptions.

The novel coronavirus (COVID-19) caused a certain number of deaths within the French population. With 29,101 victims, the Paris Region, Île-de-France, recorded the highest number of deaths in France as of June 30, 2023. On the other hand, the regions of metropolitan France least affected were those of Brittany and Corsica. For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

Medical personnel represent the largest group of workers occupationally exposed to ionizing radiation. Although the health risks associated with occupational exposure to low doses of ionizing radiation in the medical field have been investigated in several national cohorts, no study has been conducted in France to date. The ORICAMs (Occupational Radiation Induced Cancer in Medical staff) cohort is a nationwide French longitudinal cohort of medical workers exposed to ionizing radiation aiming to investigate the risk of radiation-associated cancer and non-cancer mortality. The ORICAMs cohort was set up in 2011 and includes all medical personnel monitored for ionizing radiation exposure with at least one dosimetric record in the SISERI database (the national registry for monitoring ionizing radiation exposure in workers) over the period 2002–2012. Causes of death were abstracted from death certificates and coded according to ICD-10. The follow-up ended on 31/12/2013. Standardized mortality ratios (SMRs) were calculated by cause of death to compare the mortality in the cohort to that in the French population, by gender, age group and calendar period. Among the 164,015 workers included in the cohort (60% women) a total of 1,358 deaths (892 in male and 466 in female) were reported. The observed number of all-cause deaths was significantly lower than expected based on national rates in both male (SMR = 0.35; 95% CI: 0.33, 0.38; ndeaths = 892) and female (SMR = 0.41; 95% CI: 0.38, 0.45; ndeaths = 466). This analysis leads to the conclusion that mortality in French workers exposed to medical radiation is significantly lower than the national reference rates. However, these results based on a comparative analysis with national rates may be impacted by the healthy worker effect towards low SMRs, and do not enable to establish a potential relationship between occupational exposure and mortality risk, even if we may suspect an impact of high SES of these professionals on the observed decreased mortality. Thus, further dose-response analyses based on individual ionizing radiation exposure and job’s type will be conducted to characterize correlation between risk of cancer mortality and occupational exposure.

Background: Stroke is the second leading cause of death and a first leading cause of acquired disability in adults worldwide. This study aims to evaluate the current management and associated costs of acute ischemic stroke (AIS) for patients admitted in stroke units in France and over a one-year follow-up period as well as to assess the impact of improved thrombolytic management in terms of increasing the proportion of patients receiving thrombolysis and/or treated within 3 h from the onset of symptoms. Methods: A decision model was developed, which comprises two components: the first corresponding to the acute hospital management phase of patients with AIS up until hospital discharge, extracted from the national hospital discharge database (PMSI 2011), and the second corresponding to the post-acute (post-discharge) phase, based on national treatment guidelines and stroke experts' advice. Five post-acute clinical care pathways were defined. In-hospital mortality and mortality at 3 months post-discharge was taken into account into the model. Patient journeys and costs were determined for both phases. Improved thrombolytic management was modeled by increasing the proportion of patients receiving thrombolysis from the current estimated level of 16.7 to 25% as well as subsequently increasing the proportion of patients treated within 3 h of the onset of symptoms post-stroke from 50 to 100%. The impact on care pathways was derived from clinical data. Results: Among 202,078 hospitalizations for a stroke or a transient ischemic attack (TIA), 90,528 were for confirmed AIS, and 33% (29,999) of them managed within a stroke unit. After hospitalization, 60% of discharges were to home, 25% to rehabilitative care and then home, 2% to rehabilitative care and then a nursing home, 7% to long-term care, and 6% of stays ended with patient death. Of a total cost over 1 year of €610 million (mean cost per patient of €20,326), 70% concern the post-acute phase. By increasing the proportion of patients being thrombolyzed, costs are reduced primarily by a decrease in rehabilitative care, with savings per additional treated patient of €1,462. By adding improved timing, savings are more than doubled (€3,183 per additional treated patient). Conclusions: This study confirms that the burden of AIS in France is heavy. By improving thrombolytic management in stroke units, patient journeys through care pathways can be modified, with increased discharges home, a change in post-acute resource consumption and net savings.

Standardized mortality ratiosb'*' (SMR), given for both gender and for all causes of death in the ORICAMs cohort.

The French surveillance network for causes of equine mortality (Resumeq) was created in 2015 for the qualitative surveillance of equine mortality through the centralization in a national database of necropsy data and their subsequent epidemiological analysis. It was designed to identify the causes of equine mortality, monitor their evolution over time and space, and detect emerging diseases as early as possible. Resumeq is an event-based surveillance system involving various players and structures. It is organized around a steering body, a scientific and technical support committee and a coordination unit. Different tools have been developed specifically for Resumeq. These include standardized necropsy protocols, a thesaurus for the anatomopathological terms and the causes of equine death, and an interactive web application so that network contributors can display data analysis results. The four French veterinary schools, seventeen veterinary laboratories, and ten veterinary clinics already contribute to the production and centralization of standardized data. To date, the data from around 1,000 equine necropsies have been centralized. While most deaths were located in western France, the geographic coverage is gradually improving. Data analysis allows the main causes of death to be ranked and major threats identified on a local, regional or national level. Initial results demonstrate the feasibility and benefits of this national surveillance tool. Moreover, in the future, this surveillance could take an international dimension if several countries decided to jointly capitalize on their necropsy data.

In 2022, the number of deaths due to cardiovascular disease in France was the highest in the population above 75 years of age, with approximately **** thousand deaths in the male population and around **** thousand deaths in the female population. The most common CVDs are heart attack, stroke, heart failure, arrhythmia, and heart valve complications. Symptoms of CVDs include chest pain, breathlessness, fatigue, swollen limbs, and irregular heartbeat.

In 2018, almost ***** people died on the French roads. Most of these people found death in an accident involving a driver under the influence of alcohol. Drunk driving is one of the main causes of fatal car accidents, not only in France but also in Europe.

The influence of speed and alcohol on car accidents

In 2016, traffic accidents were the fifth cause of death in the European Union. In France, road accidents have been considered a societal issue for decades. The French Government has implemented road safety measures in order to limit high-speed and fight against driving under influence. However, these two reasons keep being the main killers on the road, particularly among young drivers. Between 2013 and 2015, more than ** percent of road fatalities caused by speed concerned drivers aged 18 to 24 years. Over the same time period, alcohol was the second main cause of fatal car accidents which involved young drivers.

The decrease of road accidents?

On a general level, the number of road fatalities in France seems to be decreasing. On the tolled motorway network, for example, the death rate per billion kilometers went from *** in 2000 down to *** in 2015. In terms of number of road traffic fatalities per 100,000 inhabitants, France is not especially well-ranked in Europe. However, it is one of the only European nations which have seen a decrease in pedestrian and cyclist fatalities from 2010 to 2016, while for the same period the decrease in road deaths reached nearly ** percent.